§1122.1. Louisiana Rare Disease Advisory Council
A. For the purpose of this Part, the following terms have the meanings ascribed to
them:
(1)"Board" means the Drug Utilization Review board established by the Louisiana
Department of Health.
(2)"Department" means the Louisiana Department of Health.
(3)"Rare disease" means any disease or condition that affects fewer than two
hundred thousand persons in the United States. Rare disease shall also mean sickle cell
disease and sarcoidosis.
B.
(1)The Louisiana Rare Disease Advisory Council is hereby created within the
Louisiana Department of Health.
(2)The Louisiana Rare Disease Advisory Council, referred to hereafter in this Part
as the "advisory council", shall serve only in a resource capacity to any public and private
agency located in thi
Free access — add to your briefcase to read the full text and ask questions with AI
§1122.1. Louisiana Rare Disease Advisory Council
A. For the purpose of this Part, the following terms have the meanings ascribed to
them:
(1) "Board" means the Drug Utilization Review board established by the Louisiana
Department of Health.
(2) "Department" means the Louisiana Department of Health.
(3) "Rare disease" means any disease or condition that affects fewer than two
hundred thousand persons in the United States. Rare disease shall also mean sickle cell
disease and sarcoidosis.
B.(1) The Louisiana Rare Disease Advisory Council is hereby created within the
Louisiana Department of Health.
(2) The Louisiana Rare Disease Advisory Council, referred to hereafter in this Part
as the "advisory council", shall serve only in a resource capacity to any public and private
agency located in this state that provides services for a person who has been diagnosed with
a rare disease.
(3) The advisory council shall be composed of the following members:
(a) One member appointed by the president of the Senate.
(b) One member appointed by the speaker of the House of Representatives.
(c) Members appointed by the governor as follows:
(i) One representative from the department.
(ii) Two representatives from academic research institutions in this state that conduct
rare disease research.
(iii) Two physicians who are licensed and practicing in this state with experience in
researching, diagnosing, or treating rare diseases.
(iv) One geneticist who is licensed and practicing in this state.
(v) One registered nurse or advanced practice registered nurse who is licensed and
practicing in this state and has experience treating rare diseases.
(vi) Two residents of this state who are eighteen years of age or older and who have
either been diagnosed with a rare disease or is a caregiver for a person who has been
diagnosed with a rare disease.
(vii) One representative of a rare disease patient organization operating in this state.
(4) The governor shall determine who serves as the chair and vice chair of the
advisory council.
(5) To the extent practicable, every organization or entity that provides a nomination
to the advisory council shall strive for diversity in its appointment on the basis of race,
ethnicity, sex, professional or educational background, and geographic residency.
C. The advisory council shall hold its initial meeting no later than October 1, 2021.
The advisory council shall meet at least quarterly in a calendar year and at any other time as
it deems necessary.
D. The purposes of the advisory council include all of the following:
(1) To provide input and feedback to the department and any other state agency on
matters that affect a person who has been diagnosed with a rare disease, including but not
limited to all of the following:
(a) Pandemic preparedness and response and its impact on a person living with a rare
disease.
(b) Research, education, diagnosis, and treatment relating to rare diseases within this
state.
(c) Rare diseases in general, the severity of rare diseases, and unmet medical needs
associated with rare diseases.
(d) The demographics and clinical description of patient populations.
(e) Timely access to screening, care, insurance or Medicaid coverage, specialists, and
other needed services for a patient who has been diagnosed with a rare disease.
(f) The impact that coverage, cost-sharing, tiering, and any other utilization
management procedure has on providing treatment and services to a patient who has been
diagnosed with a rare disease.
(2) To provide expert and clinical advice to the board in its review of treatments for
a rare disease. The treatments may include drugs or biological products emerging from fields
of personalized medicine and non-inheritable gene editing therapeutics.
(3) To provide a report to the governor, the Legislature of Louisiana, the department,
and any other relevant agency of both of the following:
(a) Any findings, activities, and progress of the advisory council pursuant to the
provisions of Paragraphs (1) and (2) of this Subsection.
(b) Any recommendations for addressing the needs of a person living with a rare
disease in this state.
E. The advisory council shall not have authority on any matter relating to the
department or the board.
F. Nothing in this Section shall require the board to follow the recommendations of
the advisory council.
G. Nothing in this Section shall require the advisory council, the board, or any state
agency to consult with a person on any matter or be required to meet with any specific expert
or stakeholder.
H. An advisory council member shall not receive any compensation for serving on
the advisory council.